Compile Data Set for Download or QSAR
Report error Found 562 Enz. Inhib. hit(s) with Target = 'Interleukin-1 receptor antagonist protein'
TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686658(US20240246937, Example 103)
Affinity DataEC50:  11nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686659(US20240246937, Example 104)
Affinity DataEC50:  4nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686660(US20240246937, Example 105)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686661(US20240246937, Example 106)
Affinity DataEC50:  7nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686662(US20240246937, Example 107)
Affinity DataEC50:  13nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50611546(CHEMBL5265950 | US20240246937, Example 108)
Affinity DataEC50:  20nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686664(US20240246937, Example 109)
Affinity DataEC50:  24nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686665(US20240246937, Example 110)
Affinity DataEC50:  27nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686666(US20240246937, Example 111)
Affinity DataEC50:  8nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686667(US20240246937, Example 112)
Affinity DataEC50:  7nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686668(US20240246937, Example 113)
Affinity DataEC50:  15nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686669(US20240246937, Example 114)
Affinity DataEC50:  7nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686670(US20240246937, Example 115)
Affinity DataEC50:  4nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686671(US20240246937, Example 116)
Affinity DataEC50:  17nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686672(US20240246937, Example 117)
Affinity DataEC50:  14nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686673(US20240246937, Example 118)
Affinity DataEC50:  7nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686674(US20240246937, Example 119)
Affinity DataEC50:  4nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686675(US20240246937, Example 120)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686676(US20240246937, Example 121)
Affinity DataEC50:  7nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686677(US20240246937, Example 122)
Affinity DataEC50:  6nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686678(US20240246937, Example 123)
Affinity DataEC50:  5nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686679(US20240246937, Example 293 | US20240246937, Exampl...)
Affinity DataEC50:  7nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686680(US20240246937, Example 125)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686681(US20240246937, Example 126)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686682(US20240246937, Example 127)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686683(US20240246937, Example 128)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686684(US20240246937, Example 129)
Affinity DataEC50:  6nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686685(US20240246937, Example 130)
Affinity DataEC50:  5nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686686(US20240246937, Example 131)
Affinity DataEC50:  9nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686687(US20240246937, Example 132)
Affinity DataEC50:  15nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686688(US20240246937, Example 133)
Affinity DataEC50:  22nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686689(US20240246937, Example 134)
Affinity DataEC50:  40nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686690(US20240246937, Example 135)
Affinity DataEC50:  6nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686691(US20240246937, Example 136)
Affinity DataEC50:  20nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686692(US20240246937, Example 137)
Affinity DataEC50:  6nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686693(US20240246937, Example 138)
Affinity DataEC50:  12nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686694(US20240246937, Example 139)
Affinity DataEC50:  26nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686695(US20240246937, Example 140)
Affinity DataEC50:  36nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686696(US20240246937, Example 141)
Affinity DataEC50:  23nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686697(US20240246937, Example 142)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686698(US20240246937, Example 143)
Affinity DataEC50:  15nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686699(US20240246937, Example 144)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50611547(CHEMBL5266457 | US20240246937, Example 145)
Affinity DataEC50:  1nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686701(US20240246937, Example 146)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686702(US20240246937, Example 147)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686703(US20240246937, Example 148)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686704(US20240246937, Example 149)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686705(US20240246937, Example 150)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686706(US20240246937, Example 151)
Affinity DataEC50:  1nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686707(US20240246937, Example 152)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 562 total ) | Next | Last >>
Jump to: